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Background: Patients with type 2 diabetes (T2DM) often experience depression during
treatment, negatively influencing their treatment compliance and clinical outcomes.
Recently, the pay-for-performance (P4P) program for chronic diseases, with high-cost
and high-risk feature, such as T2DM, has been implemented and has been operational
for several years. Nevertheless, its effect on the risk of developing depression among
T2DM cases is unknown. This study aims to explore the association of P4P use with the
subsequent risk of developing depression among these patients.
Methods: This cohort study used a nationwide health insurance database to identify
patients 20–70 years of age newly diagnosed with T2DM who enrolled in the P4P
program between 2001 and 2010. From this group, we enrolled 17,022 P4P users
and then 17,022 non-P4P users who were randomly selected using propensity-score–
matching. Enrolled patients were followed until the end of 2012 to record the occurrence
of depression. The Cox proportional hazards regression was utilized to obtain the
adjusted hazard ratio (aHR) for P4P use.
Results: During the study period, a total of 588 P4P users and 1,075 non-P4P users
developed depression at incidence rates of 5.89 and 8.41 per 1,000 person-years,
respectively. P4P users had a lower depression risk than did non-P4P users (aHR, 0.73;
95% Confidence Interval, 0.65–0.80). This positive effect was particularly prominent in
those receiving high-intensity use of the P4P program.
Conclusion: Integrating P4P into routine care for patients with T2DM may have
beneficial effects on curtailing the subsequent risk of depression.
Keywords: type 2 diabetes, pay-for-performance, depression, cohort study, risk
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INTRODUCTION
Depression is a chronic mental disorder that impacts cognitions,
moods, behaviors, and physical well-being, thereby affecting
quality of life (1). Depression affects approximately 350 million
people worldwide and is particularly common among individuals
with chronic diseases (2). For example, the association between
depression and type 2 diabetes (T2DM) has been recognized for
many years. One epidemiological study suggested that at least
one-third of people with diabetes suffer from clinically relevant
depressive disorders (3). A meta-analysis of 11 studies reported a
24% increased risk of incident depression in people with T2DM,
compared to those without T2DM (4). Notably, the combination
of diabetes and depression poses critical clinical challenges to the
healthcare system. T2DM patients suffering from concomitant
depression have an estimated 52% increase ($10,016 vs. $15,155)
in annual medical expenses over those without depression (5),
and more than double the likelihood of mortality due to poor
glucose regulation and poor compliance with diabetes treatments
(6). Therefore, an early implementation of effective diabetes
management is important to prevent or lessen the susceptibility
to depression among such patients (7).
The present standard modality for decreasing depression
onset among diabetic patients is the use of anti-depressant
medications. Some of these medications, however, may induce
adverse side effects such as weight gain and decreased glycemic
control (4, 8, 9). In response to this, another option, the
pay-for-performance (P4P) program for patients with high-
cost and high-risk chronic diseases, has raised attention due
to its feature (10). The aim of P4P programs is to establish a
complete “patient-centered” co-care model for self-care related
to health education, consultation, referral system establishment,
and resource linking. Moreover, in order for the patient to
stabilize the disease and improve quality of life, it is necessary
to actively participate in programs, and regularly follow-up with
case management, allowing patients to receive regular visits
and evaluate physician-prescribed medications to reduce the
development of any complications (11). A growing body of
scientific evidence indicates that implementing P4P significantly
increases the quality and satisfaction of medical care for diabetic
patients (12), and diminishes the burden of disease-generated
complications (13, 14). At present, no data are available on
the success of P4P in decreasing the risk of depression among
T2DM patients. To address this concern, we used a national
insurance database to compare depression risks between patients




The Longitudinal Health Insurance Database (LHID) was
utilized as the data source in this retrospective cohort study.
The LHID is a sub-dataset of the National Health Insurance
Research Database (NHIRD) of Taiwan, made up of one million
randomly sampled people with over 10 years of available follow-
up data. It has been established that these recruited individuals
have similar age and sex distributions to the general population
of Taiwan because of a multistage stratified systematic sampling
method performed by the Bureau of National Health Insurance
(NHI) to ensure the representativeness of the sampling (15).
This database has been previously used in numerous research
reports (16, 17). This database compiled (i) demographic
information of enrollees; (ii) health insurance claims data;
(iii) diagnostic codes; (iv) contracted pharmacies; and (v)
medical examination information on persons under the NHI
program. This study was conducted in accordance with the
Helsinki Declaration, and was approved by the local institutional
review board and ethics committee of Buddhist Dalin Tzu Chi
Hospital (No. B10004021-3).
Study Population
Patients 20–70 years of age, newly-diagnosed with T2DM
between 2001 and 2010 were identified (Figure 1). To ensure
the accuracy of diagnoses, patients with T2DM were identified
if they had at least three ambulatory or one inpatient claims with
the International Classification of Disease, 9th Edition, Clinical
Modification (ICD-9-CM) diagnosis code 250 without type 1
diabetes (ICD-9-CM code 2501). A total of 1,540 patients with
T2DMwere excluded because of previous diagnosis of depression
(ICD-9-CM code 296.2, 296.3, 300.4, or 311). In accordance
with the rationale in identifying T2DM cases, we only selected
participants who had at least three outpatient visits, or at least
one inpatient claim due to depression (ICD-9-CM code 296.2,
296.3, 300.4, or 311), dating from 1996, when the computerized
claims data from the LHID became available, until the date of
cohort entry. Those with a follow-up period <12 months were
also excluded (n= 345). Overall, we enrolled 63,853 subjects with
new-onset T2DM.
Healthcare claim data for all included patients were
reviewed to determine whether the P4P model had been
used following the onset of T2DM. Patients were considered
as P4P users if their claim files were noted with the code
of “E4” in the treatment claims after diabetes onset (13),
whereas the remaining subjects were classified as non-P4P
users. In Taiwan, P4P has been applied to several chronic
diseases, including diabetes (13, 14) and schizophrenia (18,
19). P4P has been launched into routine clinical practice
since 2001, with the aim of providing holistic care to
complex or high-resource patients, particularly those with T2DM
(20). This program integrated a multi-component intervention
comprised of medical history, evaluation of management plan,
diabetes self-management education and periodic laboratory
evaluations. These evaluations contained results from blood
sugar, hemoglobin A1c (HbA1c), low-density lipoprotein,
triglycerides, serum creatinine, urine albumin/creatinine ratio,
systolic and diastolic blood pressures, eye examination, and foot
examination for initial enrollment visit. Furthermore, several
of these examinations, including blood sugar, HbA1c, and
systolic and diastolic blood pressures, are performed every 3
months for care visit continuity (20). Taken together, the P4P
program is patient-tailored and includes assessments, planning,
integration, implementation, and follow-up evaluations of
treatment plans via closer collaboration between clinical
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FIGURE 1 | Flow chart of selection and follow up of study subjects.
specialists, such as physicians, certified diabetes educators, and
registered dietitians, allowing participants to follow regular visits
and healthcare providers to evaluate medication compliance
and effect.
In this study, 18,594 patients were categorized as P4P users.
A comparison cohort was randomly selected from the remaining
insured T2DM cases without the involvement of P4P. To ensure
comparability of samples, we utilized the propensity score (PS)
with a 1:1 matching method to balance the characteristics
between the P4P and non-P4P groups. We used multivariable
logistic regression models to estimate PS-value according to all
baseline characteristics (listed in Table 1) as covariates included
in the model. Patients were matched by PS using one-to-one
nearest neighbor matching within 0.2 caliper distance, in which,
pairs of user and non-user were formed, such that matched
subjects have similar values of each propensity. Afterwards, an
equal number of P4P and non-P4P patients were analyzed in
this study. Additionally, to consider immortal time bias that
may bias the results in favor of the treatment group (21), the
index date for the follow-up period for non-P4P users was
the date of T2DM diagnosis, while that for P4P users was
defined as the date of initiation of P4P use. The end date
of the follow-up period for both groups was the earliest of
the following: (a) a diagnosis of depression; (b) withdrawal
from the insurance program; or (c) the date of December 31,
2012.
Definition of Other Covariates
Information on potential confounders included age, sex, monthly
income (for estimating insurance payment), the urbanization
level of enrollees’ residential area, and former comorbidities.
Monthly income was separated into three classes (class 1 [lowest
income] to class 3 [highest income]). The urbanization level was
classified into seven grades, as outlined in a previous study (22),
with a higher grade indicating a more urban environment. In
this study, we divided urbanization into three levels, namely,
high (metropolitan cities), medium (small cities and suburban
areas), and low (rural areas). Baseline comorbidities for each
subject were determined by individual medical records in the
year preceding cohort entry, which included hypertension (ICD-
9-CM 401-405), obesity (ICD-9-CM 278.0), stroke (ICD-9-CM
430-438), heart disease (ICD-9-CM 410-429), chronic kidney
disease (ICD-9-CM 585), rheumatologic disorders (ICD-9-CM
725-729), and cancer (ICD-9-CM 140-208).
Statistical Analysis
Categorical variables are reported as frequency and/or
percentage, and continuous variables are presented as mean
with standard deviation (SD). In step one of the analyses,
Chi-square test and t-test were used to examine the differences
in demographic variables and comorbidities between those
with and without P4P use. The incidence rate of depression
was calculated as the number of cases per 1,000 person-years.
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TABLE 1 | Demographic data and selected comorbidities of study subjects.
Variables Total Non-P4P users P4P users p
N = 17,022 N = 17,022
Age (year) 0.74
≤50 12,279 (36.1) 6,155 (36.2) 6,124 (36.0)
>50 21,765 (63.9) 10,867 (63.8) 10,898 (64.0)
Mean (SD) 53.6 ± 10.1 53.6 ± 10.2 53.6 ± 10.1 0.82
Sex 0.88
Female 16,761 (49.2) 8,388 (49.3) 8,373 (49.2)
Male 17,283 (50.8) 8,634 (50.7) 8,649 (50.8)
Monthly income 0.36
Class 1 12,802 (37.6) 6,420 (37.7) 6,382 (37.5)
Class 2 19,263 (56.6) 9,643 (56.7) 9,620 (56.5)
Class 3 1,979 (5.8) 959 (5.6) 1,020 (6.0)
Residential area 0.68
Urban 19,819 (58.2) 9,938 (58.4) 9,881 (58.0)
Suburban 5,286 (15.5) 2,650 (15.6) 2,636 (15.5)
Rural 8,939 (26.3) 4,434 (26.0) 4,505 (26.5)
Comorbidity
Hypertension 17,849 (52.4) 8,915 (52.4) 8,934 (52.5) 0.84
Obesity 621 (1.82) 315 (1.85) 306 (1.80) 0.69
Rheumatoid 350 (1.0) 239 (1.4) 211 (1.2) 0.18
Heart disease 6,311 (18.5) 3,128 (18.4) 3,183 (18.7) 0.44
Chronic kidney disease 552 (1.6) 337 (2.0) 315 (1.9) 0.38
Cancer 1,215 (3.6) 552 (3.2) 563 (3.3) 0.74
Stroke 2,324 (6.8) 1,206 (7.1) 1,218 (7.2) 0.80
Multivariate Cox proportional hazards regression was then
applied to compute the hazard ratio (HR) with 95% confidence
interval (CI) of depression risk in association with P4P use.
To test the robustness of the relationship between P4P use and
subsequent depression risk, we summed the total number of
P4P use and categorized P4P usage as low, medium, or high
based on the tertile distribution of P4P use. The assumption of
proportional hazards was confirmed by plotting the graph of
the survival function vs. the survival time and the graph of the
log, log (survival), vs. the log of survival time. Statistical analyses
were performed using SAS Version 9.3 software (SAS Institute
Inc., Cary, NC, USA), with p < 0.05 considered significant.
RESULTS
The analysis included data from 17,022 P4P users and 17,022
non-P4P users. Analysis of the distributions of pertinent
characteristics between the two groups, including age, sex,
monthly income, residential area, and comorbidities, indicates
that the two groups were comparable with respect to these
characteristics (Table 1). The mean age for P4P users and non-
P4P users were 53.6 ± 10.2 and 53.6 ± 10.1 years, respectively.
The sex ratio was approximately 1:1 betweenmales and females in
both cohorts. The majority of participants had monthly income
levels of Class 2 (56.6%) and tended to live in more urbanized
areas (58.2%). The primary comorbidity in both cohorts was
hypertension (52.4%), followed by heart disease (18.5%), and
stroke (6.8%).
Among all eligible T2DM subjects, a total of 1,663 first
episodes of depression occurred, 1,075 in non-P4P users and 588
in P4P users during follow-up periods of 127820.16 and 99788.27
person-years, respectively. The incidence rate of depression was
found to be significantly lower in P4P users than in non-P4P
users (5.89 vs. 8.41, respectively, per 1,000 person-years), with
an adjusted HR of 0.73 (95% CI: 0.65–0.80) (Table 2). Subgroup
analysis by low, medium, and high intensity of P4P use further
indicated that T2DM patients using P4P at high intensity had a
52% lower risk of depression (95% CI: 0.41–0.58).
We performed an additional stratified analysis by age and
sex to determine the effect of P4P on the risk of depression.
In general, the use of P4P was associated with a lower risk
of depression, regardless of subject’s sex or age. Multivariable
stratified analysis showed that the likelihood of decreased
depression was greater in males than females (adjusted HR: 0.67;
95% CI: 0.58–0.81) (Table 3).
DISCUSSION
Findings of this retrospective cohort study indicated that
depression risk was lower for T2DM patients who received P4P
than for those who did not. Multivariable analysis showed that
P4P use was associated with a 73% lower risk of depression
among T2DM subjects. High-intensity use of P4P had markedly
greater benefits, with a 52% lower risk of depression. As a
dose-response relationship is considered strong evidence for a
causal relation between exposure level and outcome, this finding
suggests that P4P use is indeed successful in decreasing the
likelihood of depression. While studies on this issue are scarce,
this positive therapeutic effect is consistent with earlier reports
and adds to a growing body of evidence regarding the clinical
effectiveness of P4P (12–14, 23).
We suggest several potential reasons for the beneficial effect of
P4P on depression risk in this study. First, a unique difference
between the P4P program and conventional treatment is that
the former utilized a highly interactive approach to more
actively engage T2DM patients with educational and therapeutic
information, throughout the post-implementation period (10,
20). This approachmight be beneficial in instituting individually-
tailored, need-based strategies for these patients to increase their
acceptance of T2DM and ultimately improve their psychological
adjustment. Of the studies conducted thus far, some have
shown that interventions such as structured self-monitoring
of blood glucose, consecutive group-based counseling, and an
education program were related to lower risks of depression
following T2DM diagnosis (7, 24). Second, the continuity of
care embedded in P4P is reported to enable diabetic patients
to maintain good metabolic control, especially of their HbA1c
levels (25). For diabetic patients, higher HbA1c is thought to
correlate with a higher risk of developing depression (26, 27).
Previous studies have shown that patients with poorly controlled
diabetes commonly had higher levels of the pro-inflammatory
cytokines tumor necrosis factor-α (TNF-α), interleukin 1
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TABLE 2 | Risk of depression for T2DM patients with and with no use of P4P program.
Patient group N Events Person-years Incidence Adjusted HR* (95% CI)
Non-P4P users 17,022 1,075 127820.16 8.41 1
P4P users 17,022 588 99788.27 5.89 0.73 (0.64–0.83)
Low intensity 8,497 287 42338.85 6.78 0.85 (0.75–0.98)
Medium intensity 4,425 163 24126.49 6.76 0.84 (0.71–0.97)
High intensity 4,100 138 33322.93 4.14 0.48 (0.41–0.58)
*Model adjusted for sex, age, residential area, monthly income, and comorbidities.
TABLE 3 | Incidence and depression risk for T2DM patients with and with no P4P use stratified by sex and age.
Variables Non-P4P users P4P users Adjusted HR (95% CI)
Patients Person-years Incidence Case Person-years Incidence
Sex
Female 652 62988.59 10.35 372 49585.20 7.50 0.75Y
(0.65–0.84)
Male 423 64831.57 6.52 216 50203.07 4.30 0.67Y
(0.58–0.81)
Age
≤50 347 44602.88 7.78 192 34874.25 5.51 0.74*
(0.62–0.89)
>50 728 83217.28 8.75 396 64914.02 6.10 0.73*
(0.63–0.87)
Y Model adjusted for age, residential area, monthly income, and comorbidities.
*Model adjusted for sex, residential area, monthly income, and comorbidities.
(IL-1), IL-6, and HbA1c-values (28, 29). These mediators may
play important roles in the pathogenesis of neuropsychiatric
symptoms, especially depression (30).
Age-and sex-specific analyses showed that P4P provides
greater benefits for male subjects. Two reasons may account for
this phenomenon. First, women have been shown to be more
health-conscious than men and thus may be more likely to
pursue treatment at the earliest notice of medical irregularity
(31), thereby lessening or moderating the preventive effect of
the P4P program in influencing depression onset. In addition,
females may benefit from inherent estrogen, which is known to
suppress production of the inflammatory cytokines IL-1, IL-6,
and TNF-α (32), which may affect the effect of P4P among them.
As previously described in the Methods section, the
database used in this study has several strengths, including its
representativeness of the entire Taiwanese population and the
large sample size that ensured reliable findings. In addition,
this study is the first to investigate the relationship between
P4P use and depression risk in patients with T2DM by using a
longitudinal cohort study design, thus allowing us to robustly
examine the relationship between high intensity P4P use and
the risk of depression among such patients. Nonetheless, several
limitations of this study merit attention. First, the use of
secondary health care databases might pose the risk of errors
in the coding process. To diminish this potential risk, the
disease of interest in this study, namely T2DM, as well as the
manifestations of depression and comorbidities, were identified
if it ever occurred at a minimum of three outpatient visits,
or if, at least, one inpatient admission during the follow-
up period was recorded. Additionally, the NHI of Taiwan
randomly reviews the charts and audits medical charges to
verify the accuracy of claims (15). Moreover, because the
coding approach and data availability were similar for the
two cohorts, it could be argued that this similarity would
only tend to underestimate, rather than overestimate, the
magnitude of exposure—disease association. Second, the LHID
lacks information on social network relationships, family history,
personality attributes, laboratory data, and body mass index.
Thus, we used several available comorbidities as surrogates to
address these unmeasured confounders. For example, obesity
and hypertension were used to substitute for the influence of
body mass index and physical inactivity (33). Future research,
however, addressing these factors is needed to expand on these
preliminary findings. Third, although our study revealed a
substantial benefit resulting from the use of P4P for T2DM
patients, it must be recognized that these participants were not
randomly categorized into users and non-users. Data derived
from a retrospective cohort study are generally of lower statistical
quality than those derived from randomized trials because of
potential biases. Therefore, caution should be exercised when
interpreting the findings. A large-scale randomized controlled
trial is, therefore, recommended to better determine the
efficacious influence of P4P on other psychiatric disorders among
diabetic patients.
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CONCLUSION
This large-scale cohort study is the first to clarify whether
adding the P4P into the routine care process could lessen
the subsequent depression risk among T2DM patients. Our
results show that the implementation of P4P indeed decreases
the subsequent risk of depression by 27%. Notably, we
observe an additional positive effect associated with high-
intensity P4P for such patients. The current study provides
further evidence that the integration of P4P programs
into routine disease management may be beneficial for
achieving treatment goals and reducing costs for patients with
chronic diseases.
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